Table 1 Patient characteristics

Age (years)

62 (51; 68)

Sex (males/females)

2/40

Disease duration (years)

16 (7; 23)

Current/prior/never smokers (%)

20/41/39

Anti-SS-A antibody seropositives (%)

76

Anti-SS-B antibody seropositives (%)

48

ANA seropositives (%)

79

RF seropositives (%)

52

IgG (g/L)

13.1 (10.0; 17.1)

Complement component 3 (g/L)

1.00 (0.89; 1.15)

Complement component 4 (g/L)

0.16 (0.12; 0.21)

Lip biopsy—focus score ≥ 1 (N positives/N studied (%))

28/33 (85)

ESSDAI total score

6 (1; 12)

ESSPRI total score

6 (5; 8)

Fecal calprotectin (μg/g)

38 (20; 123)

Irritable bowel syndrome-like symptoms (%)

42

Using proton pump inhibitors (%)

36

Using NSAIDs (%)

38

Using glucocorticoids (%)

36

  > 5 mg prednisolone daily

7

 5 mg prednisolone daily

24

  < 5 mg prednisolone daily

5

Using anti-malarials (%)

29

Using other DMARDs (%)

2